Acute Lung Injury Market Size, Trends & Forecast 2034
Coverage: Acute Lung Injury Market covers analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others) and Geography
- Report Date : Apr 2026
- Report Code : TIPRE00015798
- Category : Life Sciences
- Status : Upcoming
- Available Report Formats :
- No. of Pages : 150
The Acute Lung Injury Market size is expected to reach US$ 939.59 million in 2034 from US$ 632.7 million in 2025. The market is anticipated to register a CAGR of 4.4% during 2026–2034.
Acute Lung Injury Market AnalysisThe Acute Lung Injury (ALI) market is experiencing robust growth, primarily fueled by rising incidence of acute respiratory distress syndrome (ARDS), growing number of severe ALIs, and increasing cases of sepsis, pneumonia, and trauma worldwide. ALI therapies, such as mechanical ventilators, extracorporeal membrane oxygenation (ECMO) devices, and pharmacologic approaches, hold a key position in the intensive care unit for gas transfer and mitigating lung injuries. The evolving market is moving towards protecting the lungs with advanced ventilation practices and extracorporeal support systems to counter ventilator-induced lung injuries. Additionally, the increasing applications of ECMO from ARDS treatment for bridge therapy in lung transplant procedures will further fuel the demand. Industry players will concentrate on developing ECMO with anti-inflammatory coatings for better biocompatibility and increasing patient survival.
Acute Lung Injury Market OverviewAcute Lung Injury treatment solutions involve the use of a variety of tools and therapies aimed at facilitating the ventilation and oxygenation processes in patients who have alveolar damage. Market drivers in the sector include the adoption of precision medicine in the medical industry. Adaptive pressure modes of mechanical ventilators lead the way because the equipment can provide tidal volumes that reduce the risks of barotrauma effectively. Hospitals account for the largest market share; however, ambulatory surgical and respiratory institutes are the other markets that show promise. The market is also experiencing growth in the production of ALI treatment solutions specifically targeting newborn children who stand the greatest risks. In North America and Europe, sophisticated ALI treatment infrastructure is on the rise, leading to the adoption of highly advanced ECMO programs in large ICUs. In the Asia Pacific market, growth is driven by the mass adoption of ALI treatment solutions.
Strategic InsightsAcute Lung Injury Market Drivers and OpportunitiesMarket Drivers:
- High Global Burden of Respiratory Conditions: Increased cases of pneumonia and sepsis-associated ALI have driven the need for innovative ventilation strategies and ECMO in critical care units.
- Technological Advancements in Ventilation Modes: Innovations such as high-frequency oscillatory ventilation (HFOV) and neurally adjusted ventilatory assist (NAVA), thus decreasing VILI and increasing synchrony with ventilation.
- Rising ECMO Utilization: Expanded use of venovenous ECMO for refractory hypoxemia in ARDS patients creates a sustained need for integrated respiratory support systems.
Market Opportunities:
- Development of Portable and Wearable Devices: There are potential avenues for the development of compact ECMO machines as well as non-invasive ventilation systems specifically designed for transport or at home in the aftermath of ALI.
- Expansion in Emerging Markets: The improvement of the ICU infrastructure in the Asia Pacific and Latin American regions presents opportunities to develop relatively inexpensive treatments for ALI, given the rising cases of respiratory disorders caused by pollution.
- Integration of AI and Biomarkers: Smart ventilators with AI-driven weaning protocols and biomarker-guided therapies promise personalized ALI management.
The Acute Lung Injury Market share is analyzed across various segments to provide a clearer understanding of its structure, growth potential, and emerging trends. Below is the standard segmentation approach used in most industry reports:
By Product:
- Mechanical Ventilator: Standard ventilators for invasive and non-invasive care, using pressure-regulated volume-controlled ventilation to prevent lung overinflation.
- Fluid Management: Fluid overload is avoided by the use of the conservative approach in managing fluids, leading to a reduction in the incidence of pulmonary edema and improving ALI recovery outcomes.
- Pharmacotherapy: Anti-inflammatory drugs and vasodilators target alveolar inflammation and disrupted gas exchange mechanisms.
- Adjunctive Procedures: Positioning the patient prone and ECMO can facilitate alveolar recruitment for patients with refractory hypoxemia cases.
By End User:
- Hospitals: The main site and location for ICUs that have provided comprehensive observation for ALI.
- Ambulatory Surgical Centers: Offer assistance with acute conditions through follow-up outpatient services.
By Geography:
- North America
- Europe
- Asia-Pacific
- South & Central America
- Middle East & Africa
Market Report Scope
Acute Lung Injury Market Share Analysis by GeographyNorth America commands the largest market share, bolstered by advanced critical care networks, high ARDS incidence, and rapid adoption of ECMO protocols. Asia-Pacific is poised for the fastest growth, driven by massive populations, air pollution, and healthcare investments in countries like India and China.
North America
- Market Share: Holds the largest market share, dominated by the U.S., with its cutting-edge ICU infrastructure.
- Key Drivers:
- High ARDS prevalence from sepsis and trauma
- Robust R&D in lung-protective strategies
- Supportive reimbursement for ECMO therapies
- Trends: Growing focus on early diagnosis protocols and clinical trials targeting inflammatory lung conditions.
Europe
- Market Share: Substantial share, underpinned by universal healthcare and stringent regulatory standards.
- Key Drivers:
- Emphasis on ARDS clinical trials
- Network of specialized respiratory centers
- EU-funded innovations in ventilation tech
- Trends: Increasing adoption of lung-protective ventilation and interest in regenerative therapies.
Asia-Pacific
- Market Share: Fastest-growing region amid expanding ICU capacities.
- Key Drivers:
- Massive burden of infectious ALI cases
- Government healthcare modernization
- Rising ECMO training programs
- Trends: Expansion of ICU facilities and rising adoption of modern ventilation technologies.
South and Central America
- Market Share: Emerging with growth in major urban hospitals.
- Key Drivers:
- Increasing pneumonia and trauma incidences
- Private sector expansions
- Public health initiatives
- Trends: Transition to non-invasive ventilation in resource-limited settings.
Middle East and Africa
- Market Share: Nascent but expanding in Gulf states.
- Key Drivers:
- Oil-funded healthcare upgrades
- Medical tourism for critical care
- Awareness campaigns on ALI
- Trends: Investment in advanced critical care units and adoption of international treatment protocols.
High Market Density and Competition
The Acute Lung Injury Market is moderately fragmented, with global medtech leaders competing alongside respiratory specialists. Rivalry centers on ventilation efficiency, ECMO durability, and integration with monitoring suites over isolated products.
The competitive landscape pushes vendors to innovate via:
- Advanced algorithms mimicking natural breathing to cut weaning times and complications.
- Bundled solutions linking ventilators with ECMO for seamless ARDS escalation.
- Partnerships with trial networks to prove therapies in sepsis-ALI models.
Opportunities and Strategic Moves:
- Majors acquire startups in AI-ventilation for predictive ALI management.
- Long-term service pacts and clinician training to lock in hospital loyalty.
- Localized production to counter supply chain risks for disposables.
- GlaxoSmithKline plc.
- Stemedica Cell Technologies, Inc
- Histocell
- APEPTICO Forschung und Entwicklung GmbH
- Windtree Therapeutics, Inc.
- ReAlta Life Sciences, Inc.
- Apeiron Biologics AG
- Qx Therapeutics, Inc.
- Angion
Disclaimer: The companies listed above are not ranked in any particular order.
Acute Lung Injury Market News and Recent Developments- In July 2025, Merck and Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. Through this acquisition, Merck will add Ohtuvayre® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio.
- In June 2025, BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN), for the treatment of acute respiratory distress syndrome (ARDS). As part of the Fast Track designation, rhu-pGSN may also be made available to patients through the FDA’s Expanded Access or Compassionate Use program, offering a potential treatment option for those who are not eligible for clinical trials and have no alternative therapies.
The "Acute Lung Injury Market Size and Forecast (2021–2034)" report provides a detailed analysis of the market covering the below areas:
- Acute Lung Injury Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Acute Lung Injury Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Acute Lung Injury Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Acute Lung Injury Market
- Detailed company profiles.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Therapy and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The Acute Lung Injury Market is expected to grow at a CAGR of 4.4% during 2026–2034.
The acute lung injury market majorly consists of players like GlaxoSmithKline plc., Stemedica Cell Technologies, Inc, Histocell, APEPTICO Forschung und Entwicklung GmbH, Windtree Therapeutics, Inc., ReAlta Life Sciences, Inc., Apeiron Biologics AG, Qx Therapeutics, Inc., Angion, and Asklepion Pharmaceuticals, LLC., among others. Histocell and APEPTICO Forschung und Entwicklung GmbH are the top two companies in the market.
Key drivers encompass rising ARDS from infections and trauma, ECMO adoption surges, and innovations in lung-protective mechanical ventilation.
North America leads due to superior ICU infrastructure, while Asia-Pacific grows fastest from high disease prevalence and investments.
Future trends include AI-powered predictive ventilation, wearable ECMO prototypes, and biomarker-driven therapies for personalized ARDS management.
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For